Quantitative estimation of the effects of bile salt surfactant systems on insulin stability and permeability in the rat intestine using a mass balance model.
The oral delivery of peptides and proteins is compromised by chemical and proteolytic instability as well as by permeability limitations. The aim of this study was to delineate the relative contributions of simple bile salt and bile salt:fatty acid mixed micellar systems to protein stability vs permeability enhancement in the rat intestine. Insulin disappearance from the rat intestine was evaluated when administered in simple micellar systems of sodium cholate (NaC), sodium taurocholate (NaTC) and sodium glycocholate (NaGC), and in mixed micellar systems of these bile salts and linoleic acid (LA). In-vitro stability studies were used to evaluate the extent of insulin degradation in the different micellar systems. After correction for insulin degradation in all systems a mass balance model was used to estimate the fractions of insulin absorbed for all systems. Mass balance estimates for the extent of insulin absorption in control perfusion systems were consistent with previously reported predictions of the model for ileal insulin absorption. Mass balance estimates for NaGC suggested no significant effects on the fraction of insulin absorbed relative to control. However, insulin absorption was estimated to occur to a significantly greater extent for NaTC simple micellar systems and was coincident with increased permeability of the hydrophilic marker molecule PEG 4000. The mass balance model estimated higher fractions of insulin absorbed for all mixed micellar systems in line with enhanced plasma insulin levels and higher PEG 4000 permeabilities for these systems.
Lane
Majella E
ME
School of Pharmacy, Trinity College, Dublin 2, Ireland. lanem@tcd.ie
O'driscoll
Caitriona M
CM
Corrigan
Owen I
OI
D000818:Animals; D001647:Bile Acids and Salts / Q000737:chemistry / Q000493:pharmacokinetics*; D002463:Cell Membrane Permeability / Q000187:drug effects; D002626:Chemistry, Pharmaceutical / Q000379:methods; D004337:Drug Carriers / Q000493:pharmacokinetics; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004355:Drug Stability; D006000:Glycocholic Acid / Q000737:chemistry / Q000493:pharmacokinetics; D006801:Humans; D007328:Insulin / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics*; D007494:Ireland; D007583:Jejunum / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D019787:Linoleic Acid / Q000737:chemistry / Q000493:pharmacokinetics; D008297:Male; D008823:Micelles; D008956:Models, Chemical; D051381:Rats; D017208:Rats, Wistar; D013501:Surface-Active Agents / Q000737:chemistry / Q000493:pharmacokinetics*; D013656:Taurocholic Acid / Q000737:chemistry / Q000493:pharmacokinetics; D013678:Technology, Pharmaceutical / Q000379:methods
D001647:Bile Acids and Salts; D004337:Drug Carriers; D004338:Drug Combinations; D007328:Insulin; D008823:Micelles; D013501:Surface-Active Agents; D013656:Taurocholic Acid; D019787:Linoleic Acid; D006000:Glycocholic Acid